DUBLIN--(BUSINESS WIRE)--The "Sciatica - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
Sciatica - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Sciatica in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Sciatica from 2017 to 2028 segmented by the seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The Sciatica market report gives the thorough understanding of Sciatica by including details such as disease introduction, symptoms, pathophysiology and mechanism, biomarkers, diagnosis and differential diagnosis.
According to the Centers for Disease Control and Prevention (CDC), pain is a leading cause of disability and a major contributor to health care utilization. It is often associated with a wide range of injury and disease. Worldwide, the ages lived with disability caused by low-back pain have increased by 54% between 1990 and 2015.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Sciatica in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:
The disease epidemiology covered in the report is segmented by:
- Diagnosed Prevalence of Sciatica
- Lumbar Disc Herniation Cases
- Gender-specific Diagnosed Prevalence of Sciatica
- Age-specific Diagnosed Prevalence
Vahdatinia et al. conducted a study titled Treatment Options for Sciatica: Surgery, Epidural Injections, and Osteopathic Manipulative Treatment that compared patients suffering from sciatica for 6-12 weeks who underwent early microdiscectomy (approximately 2 weeks) versus those who followed prolonged conservative treatment. The patients undergoing early surgery reported faster relief of leg pain at 3 months and had a median recovery time of 4 weeks and up to 1-2 years follow-up, there were no differences between the two groups. Another study in the same follows up for both the conservative group and surgery group improved with regards to primary (leg and/or back pain, perceived recovery, leg pain-specific functional status) and secondary outcomes with no statistically significant differences. On average, 80% of patients were able to avoid surgical intervention with the help of epidural injection treatment.
A German study conducted by Henschke et al. titled The Epidemiology and Economic Consequences of Pain stated that in children and adolescents, the cases reported were of 1 year incidence of low-back pain ranging from 11.8% to 33.0%, with the 1 month prevalence ranging from 9.8% to 36.0%. In addition to this, a survey published showed that over 400,000 children and adolescents aged 11-15 years reported the 1 month prevalence of low-back pain to be 37%. The incidence of sciatica over 1 year was reported to be 9.3% and the 1 month prevalence of sciatica ranges from 0.4% to 16.4%.
Sciatica Drug Chapters
This segment of the Sciatica report encloses the detailed analysis of pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Sciatica and awareness of the disease. The overall dynamics of Sciatica market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Semnur Pharmaceuticals and Seikagaku Corporation will significantly increase the market during the forecast period (2019-2028).
Sciatica Market Outlook
Sciatica is characterized by radiating posterior or posterolateral leg pain, which is sometimes accompanied by back pain, sensory loss, weakness, or reflex abnormalities. The nerve branches from the spine to the left and right buttocks and then travel down the back of the legs, at about the middle of the thighs, to the feet. Sciatica pain greatly affects the quality of life of the people since it is difficult to know and diagnose the root cause.
The treatment for sciatica majorly includes nonsurgical and surgical protocols, wherein, nonsurgical protocol includes physical therapy and medications. Bed rest has been traditionally supported for the treatment of acute sciatica. While the surgical protocol is the last option to be followed as patients do not get relief from nonsurgical interventions.
First-line treatments of sciatica typically include some combination of physical therapy, medications, therapeutic injections, and alternative therapies. A wide array of passive options are available such as deep tissue massage, hot and cold therapies, transcutaneous electrical nerve stimulation, ultrasound, hydrotherapy. Cognitive behavior therapy (CBT) is a form of psychotherapy that explores and improves the connection between thoughts, emotions, and behaviors. The commonly followed interventions to treat sciatica include pain relievers, muscle relaxants, anti-inflammatories, antidepressants, calcium channel a2-d ligands, epidural steroids, opioids, and topical pain medications.
This segment gives a through detail of market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the market of Sciatica in 7MM is expected to change from 2019-2028.
Sciatica Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for sciatica such as SP-102 (Semnur Pharmaceutical) and Condoliase (Seikagaku Corporation) in the forecast period [2019-2028] will also create a positive impact on the sciatica market.
Key Topics Covered:
1. Key Insights
2. Sciatica Market Overview at a Glance
2.1. Market Share (%) Distribution of Sciatica in 2017
2.2. Market Share (%) Distribution of Sciatica in 2028
3. Disease Background and Overview: Sciatica
3.2. Difference between Sciatica and Lower Back Pain
3.3. Symptoms of Sciatica
3.4. Causes of Sciatica
3.4.1 Spinal Disc Herniation
3.4.2 Spinal Stenosis
3.4.4 Piriformis syndrome
3.4.6 Spondylosis and spondylolisthesis
3.4.7 Nondiscogenic causes
3.5. Pathophysiology of disk-related sciatica
3.5.1 Clinical observation
3.5.2 Physiologic Variants of Sciatica
3.6. Pathophysiological Mechanisms in Radicular Pain
3.6.1 Inflammatory mechanism
3.6.2 Immunological mechanism
3.6.3 Compressive mechanism
3.6.4 Lumbar spinal stenosis
3.6.5 Skeletal Causes of Radiculopathy
3.6.6 Lumbar bulging or herniated disc
3.7. Biomarkers for Sciatica
3.8. Diagnosis of sciatica
3.8.1 Indicators for sciatica
3.8.3 Selective Nerve Root Block (SRNB)
3.9. Differential Diagnosis
3.10. Clinical Guidelines for the Diagnosis for Sciatica
3.10.1 Clinical guideline for diagnosis for General Practice
3.11. Diagnostic algorithm
4. Epidemiology and Patient Population: Key Findings
4.1 7MM Total Diagnosed Prevalent Patient Population of Sciatica
5. Country Wise-Epidemiology of Sciatica
5.1 United States
5.1.1 Assumptions and Rationale
5.1.2 Sciatica Diagnosed Prevalence in the United States
5.1.3 Lumbar Disc Herniation Cases in the United States
5.1.4 Sciatica Gender-specific Diagnosed Prevalence in the United States
5.1.5 Sciatica Age-specific Diagnosed Prevalence in the United States
5.2 EU5 Countries
5.2.1 Assumptions and Rationale
5.7 United Kingdom
6.1 Nonsurgical Treatment for Sciatica
6.1.1 Physical therapy
6.1.2 Psychological therapies
6.2 Surgical Treatment of Sciatica
7 The American College of Physicians (ACP) Guidelines for the Treatment of Low Back Pain
7.1 Grading the Evidence and Developing Recommendations
7.2 Comparative Benefits of Pharmacologic Therapies
7.3 Comparative Benefits of Nonpharmacologic Therapies
8 The National Institute for Health and Care Excellence (NICE) Treatment Guidelines
9 Unmet Needs
10 Emerging Drugs
10.1 Key Cross Competition
10.2 SP-102 (Semdexa): Semnur Pharmaceuticals/Scilex Holding Company
10.2.1 Product Description
10.2.2 Other Developmental Activities
10.2.3 Clinical Development
10.2.4 Product Profile
10.3 SI-6603 (Condoliase): Seikagaku Corporation
- Seikagaku Corporation
- Semnur Pharmaceuticals/Scilex Holding Company
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9lidgd